You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Angelo Ruggiero
 + 2208 word(s) 2208 2022-02-18 03:29:11 |
2 Adjust the reference format
Lindsay Dong
 Meta information modification 2208 2022-03-23 02:36:37 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ruggiero, A. Paradoxical Hidradenitis Suppurativa during Biologic Therapy. Encyclopedia. Available online: https://encyclopedia.pub/entry/20847 (accessed on 21 May 2025).
Ruggiero A. Paradoxical Hidradenitis Suppurativa during Biologic Therapy. Encyclopedia. Available at: https://encyclopedia.pub/entry/20847. Accessed May 21, 2025.
Ruggiero, Angelo. "Paradoxical Hidradenitis Suppurativa during Biologic Therapy" Encyclopedia, https://encyclopedia.pub/entry/20847 (accessed May 21, 2025).
Ruggiero, A. (2022, March 22). Paradoxical Hidradenitis Suppurativa during Biologic Therapy. In Encyclopedia. https://encyclopedia.pub/entry/20847
Ruggiero, Angelo. "Paradoxical Hidradenitis Suppurativa during Biologic Therapy." Encyclopedia. Web. 22 March, 2022.
Paradoxical Hidradenitis Suppurativa during Biologic Therapy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10020455

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease usually occurring after puberty with painful, deep-seated, inflammatory lesions in the apocrine gland-bearing areas of the body. Paradoxical reactions during biologic treatments may be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition.

paradoxical hidradenitis hidradenitis suppurativa paradoxical reaction biologics

1. Introduction

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, inflammatory skin disease usually occurring after puberty with painful, deep-seated, inflammatory lesions in the apocrine gland-bearing areas of the body [1][2]. HS affects about 1% of the global population. HS typically occurs after puberty, with the average age of onset in the second or third decades of life, and with a female predominance [2]. Although HS pathogenesis is still unproven, recent major research advantages have increased our knowledge of the mechanisms behind HS lesions. Particularly, follicular occlusion followed by follicular rupture has been shown to be crucial to HS development, leading to immune response activation, and resulting in typical clinical HS lesions [2][3][4]. Moreover, an increased and imbalanced cytokine production—such as interleukin (IL) 17 and tumor necrosis factor (TNF) α—as well as an unopposed type I interferon production, and a change toward a helper T cell 1/helper T cell 2 profile, may all play a role in HS and psoriasis [4][5]. Furthermore, in the last few years, many studies have hypothesized that HS may be triggered by genetic and environmental factors, including drugs [3]. Moreover, the de novo onset of HS has been reported after the administration of biologic treatments for chronic inflammatory diseases. Indeed, patients treated with biologic therapies for chronic inflammatory disorders may experience the onset of new skin diseases as paradoxical reactions. These are defined as the occurrence, during treatment with biologics, of a disease that is usually responsive to this class of drug [6][7]. Psoriasiform reaction, HS, uveitis, inflammatory bowel diseases, and Pyoderma Gangrenosum were the most commonly described paradoxical reactions during biological treatment [8]. In particular, the most commonly reported was psoriasis, which is a paradoxical skin reaction since it may be both induced and treated with anti-TNF [6][7]. In recent years, even more paradoxical adverse events have been described during treatment [7][8][9]. Since the recent increased use of biologic treatments in HS, an increased number of paradoxical HS occurrences have been reported. To date, TNF inhibitors represent the only class of biologics used in HS, particularly, adalimumab is the only biologic agent formally approved for the management of moderate to severe HS [10][11][12]. Although the use IL 17 inhibitors in HS is still off-label, in the literature, data are growing regarding their efficacy (particularly for secukinumab and ixekizumab), linked with an increasing number of paradoxical HS reactions [5][10][11].

2. Paradoxical Hidradenitis Suppurativa during Biologic Therapy

2.1. Anti-TNF α

TNF α is considered as a primary driver of the inflammatory process behind HS [12]. Indeed, significantly higher TNF α concentration was found in lesional HS skin, perilesional HS skin and the serum of HS patients compared with healthy controls, although no significant correlation between TNF α levels and disease severity, including the intensity of inflammation, has been demonstrated [13][14]. Moreover, the blockage of TNF α showed significant improvements on HS. Hence, anti-TNF α represents the only approved biologic for moderate and severe forms of HS. Many cases of paradoxical skin reactions—especially psoriasis—secondary to the use of TNF α inhibitors have already been reported, as well as other immune-mediated inflammatory diseases. Moreover, anti-TNF also represents the most reported biologic class linked with paradoxical HS.

2.2. Adalimumab

Adalimumab, a fully human monoclonal IgG1 antibody directed toward membrane-bound TNF α is the only FDA-approved biologic therapy for moderate to severe HS [6][15][16]. The approved standard dosing regimen of adalimumab is 160 mg at baseline (week 0), and 80 mg at week 2, followed by 40 mg weekly from week 4 [17][18][19][20][21]. Some cases of paradoxical HS have been reported in patients suffering from chronic inflammatory bowel diseases treated with adalimumab who developed moderate to severe forms of paradoxical HS [22][23]. Indeed, in a retrospective study including 25 patients affected by autoimmune diseases, Faivre et al. reported 12 cases of paradoxical HS during adalimumab treatment, which showed improvements after adalimumab suspension and a HS relapse when restarting the treatment [6]. Furthermore, Delobeau et al. reported four cases of patients suffering from autoimmune diseases (such as Crohn’s Disease, juvenile idiopathic arthritis, severe plaque psoriasis and ankylosing spondylitis) developing paradoxical HS under adalimumab [24]. In all these studies, females were the dominant gender [6][24][25][26][22][23]. Regarding the need for adalimumab discontinuation or not, the recently proposed algorithm management of paradoxical HS proposed to continue adalimumab in mild forms and discontinue treatments only in the case of progressive worsening or in more severe forms. In all cases, additional treatment was required to improve HS outcomes.

2.3. Etanercept

Etanercept is a dimeric fusion protein that binds to the soluble and leukocyte membrane-bound TNF α receptor. FDA approved the use of etanercept to treat moderate to severe rheumatoid arthritis, moderate to severe polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. To date, fewer cases of paradoxical HS have been reported with etanercept than adalimumab [17][27]. Particularly, Pellegrino M. et al., reported the case of a 30-year-old male diagnosed with juvenile idiopathic arthritis who developed paradoxical HS lesions during etanercept treatment [27]. Only three other cases have been reported of paradoxical HS during etanercept in patients suffering from other autoimmune diseases [17]. In all cases, etanercept suspension lead to an improvement of HS lesions and a remission after the addition of other treatments [17][27].

2.4. Infliximab

Infliximab is a chimeric monoclonal antibody approved to treat a number of autoimmune and chronic inflammatory diseases, including CD, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. Even if adalimumab still represents the only FDA-approved biologic for HS, infliximab has been demonstrated to be an effective treatment for HS and, as confirmed from recent guidelines, it could be proposed as a second line biologic treatment for moderate to severe HS (recommendation grade B; evidence level: 2) [28]. Although lower than for adalimumab, some cases of paradoxical HS have been reported [28][29]. Particularly, Savaşan et al. [28] reported the case of a young patient suffering from CD who developed, for the first time, HS lesions as a paradoxical effect of infliximab treatment [30]. Similarly, cases of paradoxical HS were reported in patients suffering from CD treated with infliximab [29][30][31][32][33].

2.5. Other Biologic Classes

Although anti-TNF still represents the only FDA-approved class of biologic treatment for moderate to severe HS, new emergent treatments have been shown to be potentially effective therapies in the management of unresponsive HS forms [10][11][34]. Hence, with the progressively increased use of these new drugs, the cases of paradoxical HS reactions are slowly increasing in the literature.

2.6. Anti-IL-17

Increased IL 17 levels have recently been found in serum of HS patients linked with a significantly increased number of IL 17-producing cells in both affected and non-affected skin of HS patients [3]. Indeed, recent clinical trials with secukinumab have been performed to evaluate its efficacy and safety in moderate to severe HS. Although the use of anti-IL 17 is still off-label in HS, data are growing in the literature regarding their efficacy (particularly for secukinumab, a fully human IgG1 kappa monoclonal antibody targeting IL 17A) [5][10][11][34][35]. With regard to paradoxical HS, few cases have been reported with the use of secukinumab [24][34][36][35]. Particularly, Navarro et al. reported the case of a patient suffering from severe psoriasis unresponsive to anti-TNF, who developed paradoxical HS lesions after secukinumab treatment [34]. Moreover, a previously published article (Marasca et al., 2019 [37]) highlighted the immunological complexity behind HS, showing the potential double pathophysiological face of secukinumab in HS, describing a case of secukinumab-induced HS and a case of HS provoked by adalimumab treatment and controlled with secukinumab therapy [36]. Hence, the real role of secukinumab in the management of HS is still not well clarified, and it is a possible trigger for paradoxical HS lesions.

2.7. Anti-IL-12/23 and Anti-IL-23

Ustekinumab is a fully human monoclonal antibody against IL 12/23, acting on Th1 and Th17 pathways [38]. Although the use of anti-IL 12/23 in the management of moderate to severe HS is still off-label, several case series and studies have been reported about its possible efficacy in unresponsive and severe HS [39][40]. Indeed, in the literature, some case reports showed the possible role of ustekinumab in HS management [40][41]. However, a phase II open label study evaluating ustekinumab use in moderate to severe HS showed only limited benefits [41]. With regard to paradoxical HS, to date only one case has been described. Particularly, Gkini et al. reported the case of a 19-year-old female treated with ustekinumab for severe psoriasis, who developed HS lesions (Hurley stage II), requiring a surgical approach [42]. Anti-IL 23 drugs (guselkumab, risankizumab, tildrakizumab) represent the latest class of biologics approved for the treatment of moderate to severe psoriasis [43][44][45][46]. To date, the efficacy and safety of anti-IL 23 in the management of HS have been described only in some case series, showing contrasting results [47][48][49][50]. Indeed, the precise role of IL 23 in HS is not yet fully understood. However, previous findings suggest that the IL 23/Th17 pathways seem to be crucial in the pathogenesis of HS, including IL 23, suggesting a potential role of anti-IL 23 in HS management [50]. With regard to paradoxical HS during anti-IL 23 treatment, no cases have been reported to date.

3. Summary

TNF-α is a proinflammatory cytokine produced by innate and adaptive immune cells, has been shown to play a central role in HS [2][3][4]. These findings result in the approval of targeted therapy (anti-TNF) for the management of most severe forms of HS [3].

Typical examples of paradoxical adverse effect are: psoriasis (such as palmoplantar pustular), psoriasiform reactions, and HS. These reactions have been mainly reported in patients during biologic treatment for rheumatoid arthritis or inflammatory bowel disease [23]. However, the exact underlying physiopathologal mechanism behind these paradoxical reactions is unknown, although it has been showed that multiple immunological pathways may be involved. Particularly, one of the most important factors behind paradoxical reactions could be cytokine imbalance, which could play a key role in the development of these paradoxical reactions [6].

Although the pathogenesis of paradoxical HS induced by biologics is still unproven, it has been observed that, in genetically predisposed individuals, the introduction of biologics may induce a modulation of the innate immune system, leading to an alteration of the cytokine balance, and an increase in pro-inflammatory cytokines [37]. Nowadays, adalimumab represents the most commonly used biologic treatment involved in the onset of paradoxical HS. Particularly, a recently published multicenter retrospective study reported paradoxical HS under biological agents, with adalimumab being responsible for 48% of new HS onset cases [6]. TNF α inhibitors may cause modification of the local cytokine balance and activate alternate pathways, namely type 1 interferon and the IL 1-related family of inflammation mediators, in selected patients. The production of IL 1b is increased up to 54-fold in conventional HS skin, compared with healthy control skin, and IL 1 receptor antagonists have shown efficacy in HS. Individual susceptibility is required if further up-regulation of the IL 1 pathway is involved in TNF α inhibition, because adalimumab reduces IL 1b levels in conventional HS. It is also important to consider that, due to the larger use of this class in the management of HS, the paradoxical reactions after their use (particularly with adalimumab) are reported most frequently, without implying that there is a higher individual risk of causing paradoxical HS. As consequence, a challenging issue is whether or not to continue anti-TNF treatment after the onset of paradoxical HS. Indeed, a management algorithm for paradoxical HS has recently been proposed which suggested to continue anti-TNF treatment in mild paradoxical HS forms, suggesting a suspension in the case of a progressive worsening, or at the beginning in more severe forms [6].

In order to clarify the role of adalimumab and other anti-TNF involved in HS paradoxical reactions, including infliximab and etanercept, an imbalance has been supposed, induced by TNF blockage in the cytokine pool and a consequent activation of type I interferon or IL 1 beta, together with the possible role of occult infections [51][52]. Although adalimumab still represents the only FDA-approved biologic therapy in HS management, it has also been recently proposed that a key role is played by the IL 17 pathway in HS pathogenesis. Indeed, increased serum levels of IL 17 have been found in patients with HS, as well as a significantly increased quantities of IL 17-producing cells in both lesional and perilesional HS skin, compared with healthy subjects [2][3]. Indeed, anti-IL 17s, particularly secukinumab and ixekizumab, have been proposed as treatment options for moderate to severe HS, being also reported as possible effective therapies in some case reports [4][5][6][7]. Furthermore, secukinumab is being investigated in a phase III trial for HS treatment. Although only a few cases have been reported, anti-IL 17 has been linked to the development of paradoxical HS [5][10][11][34][36][35][37]. Indeed, HS and inflammatory bowel diseases, such as CD, share genetic susceptibility, common clinical manifestations at the gut and skin, and some immunologic features. Some genes, for example SULT1B1 (OMIM 608436) and SULT1E1 (OMIM 600043), have been associated with HS and inflammatory bowel disease. Emerging studies have shown that HS and inflammatory bowel disease are both diseases characterized by immune dysregulation. Cytokine abnormalities, such as the elevation of IL 1, IL 6, IL 17, IL 23 and the tumor necrosis factor, are involved in HS and inflammatory bowel disease. Alteration of the microbiota, resulting in immune dysregulation, also appears to play an important role in both diseases [53]. However, the exact mechanism linking paradoxical HS manifestation and CD is still unclear.

References

  1. Kurzen, H.; Kurokawa, I.; Jemec, G.B.; Emtestam, L.; Sellheyer, K.; Giamarellos-Bourboulis, E.J.; Nagy, I.; Bechara, F.G.; Sartorius, K.; Lapins, J.; et al. What causes hidradenitis suppurativa? Exp. Dermatol. 2008, 17, 455–456.
  2. Ruggiero, A.; Fabbrocini, G.; Megna, M.; Monfrecola, G.; Marasca, C. Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS. Skin Appendage Disord. 2020, 6, 366–369.
  3. Napolitano, M.; Fabbrocini, G.; Marasca, C.; Monfrecola, G. Update on pathogenesis of hidradenitis suppurativa. G. Ital. Dermatol. Venereol. 2018, 153 (Suppl. 2), 3–7.
  4. Nikolakis, G.; Kokolakis, G.; Kaleta, K.; Wolk, K.; Hunger, R.; Sabat, R.; Zouboulis, C.C. Pathogenese der Hidradenitis suppurativa/Acne inversa . Hautarzt, 2021; 72, 658–665.
  5. Megna, M.; Ruggiero, A.; Di Guida, A.; Patrì, A.; Fabbrocini, G.; Marasca, C. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol. Ther. 2020, 33, e13756.
  6. Faivre, C.; Villani, A.P.; Aubin, F.; Lipsker, D.; Bottaro, M.; Cohen, J.D.; Durupt, F.; Jeudy, G.; Sbidian, E.; Toussirot, E.; et al. French Society of Dermatology and Club Rheumatisms and Inflammation. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J. Am. Acad. Dermatol. 2016, 74, 1153–1159.
  7. Viguier, M.; Richette, P.; Bachelez, H.; Wendling, D.; Aubin, F. Paradoxical adverse effects of anti-TNF-alpha treatment: Onset or exacerbation of cutaneous disorders. Expert Rev. Clin. Immunol. 2009, 5, 421–431.
  8. Toussirot, É.; Aubin, F. Paradoxical reactions under TNF- α blocking agents and other biological agents given for chronic immune- mediated diseases: An analytical and comprehensive overview. RMD Open 2016, 15, 1–12.
  9. Neves, J.M.; Cunha, N.; Lencastre, A.; Cabete, J. Paradoxical hidradenitis suppurativa to biologic agents: A case series and literature review. Int. J. Dermatol. 2019, 58, e226–e228.
  10. Lim, S.Y.D.; Oon, H.H. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics 2019, 13, 53–78.
  11. Odorici, G.; Pellacani, G.; Conti, A. Ixekizumab in hidradenitis suppurativa: A case report in a psoriatic patient. G. Ital. Dermatol. Venereol. 2021, 155, 788–789.
  12. Savage, K.T.; Flood, K.S.; Porter, M.L.; Kimball, A.B. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther. Adv. Chronic Dis. 2019, 10, 2040622319851640.
  13. Matusiak, L.; Bieniek, A.; Szepietowski, J.C. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm. Venereol. 2009, 89, 601–603.
  14. Van der Zee, H.H.; de Ruiter, L.; van den Broecke, D.G.; Dik, W.A.; Laman, J.D.; Prens, E.P. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-α and IL-1β. Br. J. Dermatol. 2011, 164, 1292–1298.
  15. FDA. Adalimumab . 2015. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125057s394lbl.pdf (accessed on 15 December 2021).
  16. Haslund, P.; Lee, R.A.; Jemec, G.B.E. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm. Venereol. 2009, 89, 595–600.
  17. Salvador-Rodriguez, L.; Montero-Vílchez, T.; Arias-Santiago, S.; Molina-Leyva, A. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis. Dermatology 2020, 236, 307–313.
  18. Fotiadou, C.; Vakirlis, E.; Ioannides, D. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. Clin. Cosmet. Investig. Dermatol. 2016, 9, 367–372.
  19. Ikeya, S.; Takeichi, T.; Taki, T.; Muro, Y.; Ogi, T.; Akiyama, M. Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment. Acta Derm. Venereol. 2021, 28, 101.
  20. Garcia-Melendo, C.; Vilarrasa, E.; Cubiró, X.; Bittencourt, F.; Puig, L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol. Ther. 2020, 33, e14180.
  21. Fania, L.; Morelli, M.; Scarponi, C.; Mercurio, L.; Scopelliti, F.; Cattani, C.; Scaglione, G.L.; Tonanzi, T.; Pilla, M.A.; Pagnanelli, G.; et al. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development. J. Pathol. Clin. Res. 2020, 6, 55–68.
  22. Beraldo, R.F.; Marcondes, M.B.; Baima, J.P.; Barros, J.R.; Ramdeen, M.; Saad-Hossne, R.; Sassaki, L.Y. Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease? Clin. Exp. Gastroenterol. 2020, 19, 293–298.
  23. Salvatori, S.; Marafini, I.; Monteleone, G. Paradoxical hidradenitis suppurativa in Crohn’s disease patients receiving infliximab: A case report and review of literature. Eur. J. Gastroenterol. Hepatol. 2021, 33, e1046–e1050.
  24. Delobeau, M.; Abdou, A.; Puzenat, E.; Deveza, E.; Biver-Dalle, C.; Van De Laak, A.; Roche-Kubler, B.; Vuitton, L.; Koch, S.; Wendling, D.; et al. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. J. Dermatolog. Treat. 2016, 27, 251–253.
  25. Harvin, G.; Kasarala, G. Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab. Case Rep. Gastroenterol. 2016, 10, 88–94.
  26. Martina, E.; Campanati, A.; Giuliodori, K.; Offidani, A. Hidradenitis suppurativa in Crohn’s disease during adalimumab therapy: A paradox? Acta Dermatovenerol. Alp. Pannonica Adriat. 2017, 26, 21–23.
  27. Pellegrino, M.; Taddeucci, P.; Peccianti, C.; Mei, S.; Fioravanti, A.; Fimiani, M. Etanercept inducedhidradenitis suppurativa. G. Ital. Dermatol. Venereol. 2011, 146, 503–504.
  28. Zouboulis, C.C.; Bechara, F.G.; Dickinson-Blok, J.L.; Gulliver, W.; Horváth, B.; Hughes, R.; Kimball, A.; Kirby, B.; Martorell, A.; Podda, M.; et al. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization—Systematic review and recommendations from the HS ALLIANCE working group. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 19–31.
  29. Famenini, S.; Wu, J.J. Infliximab-induced psoriasis in treatment of Crohn’s disease-associated ankylosing spondylitis: Case report and review of 142 cases. J. Drugs Dermatol. 2013, 12, 939–943.
  30. Savaşan, S.; El-Baba, M. First episode of axillary acne inversa in a teenager on infliximab therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2013, 56, e2–e3.
  31. Goischke, H.K.; Ochsendorf, F.R. Acne inversa in Crohn’s disease. Z. Gastroenterol. 2001, 39, 965–969.
  32. Martinez, F.; Nos, P.; Benlloch, S.; Ponce, J. Hidradenitis suppurativa and Crohn’s disease: Response to treatment with infliximab. Inflamm. Bowel Dis. 2001, 7, 323–326.
  33. Rosi, Y.L.; Lowe, L.; Kang, S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn’s disease. J. Dermatolog. Treat 2005, 16, 58–61.
  34. Navarro-Triviño, F.J.; Sanchez-Parera, R.; Ruiz-Villaverde, R. Secukinumab-induced paradoxical hidradenitis suppurativa. Dermatol. Ther. 2020, 33, e13150.
  35. Babino, G.; D’Ambra, I.; Fulgione, E.; Alfano, R.; Verolino, P.; Argenzino, G. Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab. Int. J. Dermatol. 2021, 61, e79–e80.
  36. Pirro, F.; Caldarola, G.; De Simone, C.; Moretta, G.; Giovanardi, G.; Peris, K. Multiple paradoxicalreactions during ixekizumab therapy. Dermatol. Ther. 2019, 32, e12852.
  37. Marasca, C.; Megna, M.; Balato, A.; Balato, N.; Napolitano, M.; Fabbrocini, G. Secukinumab and hidradenitis suppurativa: Friends or foes? J. Am. Acad. Dermatol. Case Rep. 2019, 5, 184–187.
  38. Goldburg, S.R.; Strober, B.E.; Payette, M.J. Hidradenitis suppurativa: Current and emerging treatments. J. Am. Acad. Dermatol. 2020, 82, 1061–1082.
  39. Takeda, K.; Kikuchi, K.; Kanazawa, Y.; Yamasaki, K.; Aiba, S. Ustekinumab treatment for hidradenitis suppurativa. J. Dermatol. 2019, 46, 1215–1218.
  40. Romaní, J.; Vilarrasa, E.; Martorell, A.; Fuertes, I.; Ciudad, C.; Molina-Leyva, A. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa. Dermatology 2020, 236, 21–24.
  41. Blok, J.L.; Li, K.; Brodmerkel, C.; Horvátovich, P.; Jonkman, M.F.; Horváth, B. Ustekinumab in hidradenitis suppurativa: Clinical results and a search for potential biomarkers in serum. Br. J. Dermatol. 2016, 174, 839–846.
  42. Gkini, M.A.; Bewley, A.P. Development of hidradenitis suppurativa in a patient treated withustekinumab for her psoriasis: A potential paradoxical reaction? Dermatol. Ther. 2018, 31, e12742.
  43. Megna, M.; Fabbrocini, G.; Cinelli, E.; Camela, E.; Ruggiero, A. Guselkumab in moderate to severe psoriasis in routine clinical care: An Italian 44-week real-life experience. J. Dermatolog. Treat. 2020, 31, e12742.
  44. Megna, M.; Fabbrocini, G.; Ruggiero, A.; Cinelli, E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol. Ther. 2020, 33, e14144.
  45. Ruggiero, A.; Fabbrocini, G.; Cinelli, E.; Megna, M. Guselkumab and risankizumab for psoriasis: A 44-week indirect real-life comparison. J. Am. Acad. Dermatol. 2021, 85, 1028–1030.
  46. Megna, M.; Ruggiero, A.; Camela, E.; Fabbrocini, G.; Marasca, C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol. Ther. 2020, 33, e13238.
  47. Kovacs, M.; Podda, M. Guselkumab in the treatment of severe hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2019, 33, e140–e141.
  48. Caposiena Caro, R.D.; Pensa, C.; Lambiase, S.; Candi, E.; Bianchi, L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol. Ther. 2021, 34, e15116.
  49. Licata, G.; Gambardella, A.; Buononato, D.; De Rosa, A.; Calabrese, G.; Pellerone, S.; Argenziano, G. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int. J. Dermatol. 2021.
  50. Kok, Y.; Nicolopoulos, J.; Howard, A.; Varigos, G.; Kern, J.; Dolianitis, C. Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa. Australas J. Dermatol. 2020, 61, e488–e490.
  51. Tillack, C.; Ehmann, L.M.; Friedrich, M. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- g-expressing Th1 cells and IL- 17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014, 63, 567–577.
  52. Puig, L.; Gulliver, W. Paradoxical reactions: Anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. In Adverse Reactions to Biologics; Karger Publishers: Berlin, Germany, 2018; Volume 53, pp. 49–63.
  53. Chen, W.T.; Chi, C.C. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019, 155, 1022.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Allergy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Angelo Ruggiero
View Times: 603
Revisions: 2 times (View History)
Update Date: 23 Mar 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback